永安藥業(002365.SZ):與湖北永邦簽訂2025年度設備加工及製造框架協議
格隆匯12月25日丨永安藥業(002365.SZ)公佈,鑑於潛江永安藥業股份有限公司(以下簡稱“公司”或“甲方”)與湖北永邦工程技術有限公司(以下簡稱“湖北永邦”或“乙方”)簽訂的《2024年度設備加工及製造框架協議》即將到期,因公司生產工藝改進及生產設備更新改造需要,公司擬委託湖北永邦繼續提供滿足公司及其子公司技術質量指標等要求的加工及製造業務,具體包括設備製造安裝、機電設備及管道安裝等其他相關工程業務,交易總金額不超過人民幣2,000萬元人民幣。
甲方需持續進行生產工藝改進及生產設備更新改造,為確保設備質量,保證生產設備的良好運行,全面滿足甲方生產需求,並保護製造安裝過程中的專利或非專利祕密,甲方委託乙方提供滿足技術質量指標等要求的加工及製造業務,其中具體包括設備製造安裝、機電設備及管道安裝等其他相關工程的業務。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.